Scarica l'app Stockscreener
33.56
2.56%
0.865
Dopo l'orario di chiusura:
34.22
0.655
+1.95%
Precedente Chiudi:
$32.70
Aprire:
$32.65
Volume 24 ore:
1.20M
Relative Volume:
1.19
Capitalizzazione di mercato:
$3.62B
Reddito:
-
Utile/perdita netta:
$-167.80M
Rapporto P/E:
-20.56
EPS:
-1.6323
Flusso di cassa netto:
$-144.07M
1 W Prestazione:
+6.71%
1M Prestazione:
+6.20%
6M Prestazione:
+31.42%
1 anno Prestazione:
+136.02%
Intervallo 1D:
$31.75
$33.76
Intervallo di 1 settimana:
$31.75
$33.76
Portata 52W:
$12.15
$39.96
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Nome
Edgewise Therapeutics Inc
Settore
Industria
Telefono
720-262-7002
Indirizzo
1715 38TH ST, BOULDER
Compare EWTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
33.60 | 3.52B | 0 | -167.80M | -144.07M | -1.6323 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-25 | Iniziato | Goldman | Neutral |
| 2025-07-30 | Iniziato | Raymond James | Strong Buy |
| 2025-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-30 | Iniziato | Guggenheim | Buy |
| 2025-04-02 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-01-22 | Iniziato | Stifel | Hold |
| 2024-11-22 | Iniziato | Evercore ISI | Outperform |
| 2024-03-07 | Iniziato | Piper Sandler | Overweight |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2022-08-25 | Downgrade | Goldman | Neutral → Sell |
| 2022-04-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-01-28 | Iniziato | Goldman | Neutral |
Mostra tutto
Edgewise Therapeutics Inc Borsa (EWTX) Ultime notizie
Why (EWTX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $52 - Moomoo
EWTX Stock Chart | EDGEWISE THERAPEUTICS INC (NASDAQ:EWTX) - ChartMill
Edgewise Therapeutics, Inc.Common Stock (NQ: EWTX - The Chronicle-Journal
Janus Henderson (EWTX) reports 5.5% ownership — 5.9M shares disclosed - Stock Titan
Understanding Momentum Shifts in (EWTX) - Stock Traders Daily
Edgewise Therapeutics, Inc. (EWTX) Stock Price, News, Quote & History - Yahoo Finance
Muscle disease drug developer heads to RBC healthcare event May 20 - Stock Titan
TradingKey - TradingKey
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 - Yahoo Finance
Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC Says - Moomoo
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50 - Moomoo
H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Edgewise boosts R&D spending as drug trials bear promising results - BizWest
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Edgewise Therapeutics Shares Decline Amid Wider Q1 Loss - Moomoo
Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story? - Yahoo Finance
Earnings Flash (EWTX) Edgewise Therapeutics Posts Q1 Net Loss $0.46 a Share, vs. FactSet Est of $0.49 Net Loss a Share - marketscreener.com
Edgewise Therapeutics (NASDAQ:EWTX) Beats Q1 Estimates as Long-Term Data Strengthens Case for Sevasemten - ChartMill
Edgewise Therapeutics (NASDAQ: EWTX) posts Q1 2026 net loss of $49M - Stock Titan
EDGEWISE THERAPEUTICS ($EWTX) Releases Q1 2026 Earnings - Quiver Quantitative
Edgewise Therapeutics Q1 net loss widens on higher R&D costs - TradingView
Edgewise Therapeutics 1Q 2026: Net income $(49.0M), EPS $(0.46) — 10-Q Summary - TradingView
Edgewise Therapeutics (NASDAQ: EWTX) reports Q1 2026 loss, $499.6M cash - Stock Titan
Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications - PR Newswire
Edgewise Therapeutics earnings on deck as losses widen By Investing.com - Investing.com Australia
Edgewise Therapeutics earnings on deck as losses widen - Investing.com
Truist Securities Adjusts Price Target on Edgewise Therapeutics to $52 From $46, Maintains Buy Rating - marketscreener.com
Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary - GlobeNewswire Inc.
Edgewise Therapeutics stock hits 52-week high at $39.96 By Investing.com - Investing.com Australia
Edgewise Therapeutics (EWTX) Explodes 23% on Pipeline Momentum and Strong Biotech Sentiment - International Business Times Australia
Edgewise Therapeutics CMO Donovan sells $2.09 million of stock - Investing.com India
Edgewise Therapeutics Stock Climbs On Catalyst-Rich Pipeline - timothysykes.com
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
50,000-share sale notice for EWTX (NASDAQ: EWTX) - Stock Titan
Edgewise Therapeutics CMO Donovan sells $2.09 million of stock By Investing.com - Investing.com South Africa
Raymond James Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $46 - Moomoo
Edgewise Therapeutics Cmo Sold Shares Worth Over $2.0M - TradingView
Edgewise Therapeutics (EWTX) CMO sells 55,230 shares under 10b5-1 plan - Stock Titan
Cytokinetics metrics satisfy in nHCM phase III - BioWorld News
Edgewise Therapeutics stock hits 52-week high at $39.96 - Investing.com
Edgewise Therapeutics reports inducement grants as permitted by the Nasdaq Listing Rules - marketscreener.com
Edgewise Therapeutics Reports Inducement Grants As Permitted By The Nasdaq Listing Rules - TradingView
9 new Edgewise hires receive stock options for 266,000 shares - Stock Titan
Edgewise Therapeutics Inc Azioni (EWTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Edgewise Therapeutics Inc Azioni (EWTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Donovan Joanne M. | CMO |
May 05 '26 |
Option Exercise |
7.08 |
50,000 |
354,000 |
54,367 |
| Donovan Joanne M. | CMO |
May 05 '26 |
Sale |
38.57 |
50,000 |
1,928,400 |
4,367 |
| Donovan Joanne M. | CMO |
May 04 '26 |
Sale |
31.29 |
5,230 |
163,663 |
4,367 |
| Donovan Joanne M. | CMO |
Apr 01 '26 |
Option Exercise |
7.08 |
28,662 |
202,927 |
38,259 |
| Donovan Joanne M. | CMO |
Apr 01 '26 |
Sale |
32.31 |
28,662 |
926,095 |
9,597 |
| Donovan Joanne M. | CMO |
Mar 31 '26 |
Option Exercise |
7.08 |
21,338 |
151,073 |
30,935 |
| Donovan Joanne M. | CMO |
Mar 31 '26 |
Sale |
32.12 |
21,338 |
685,308 |
9,597 |
| Donovan Joanne M. | CMO |
Mar 27 '26 |
Sale |
30.98 |
16,358 |
506,735 |
9,597 |
1.49%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):